S&P 500   3,847.31 (-1.99%)
DOW   31,510.54 (-1.41%)
QQQ   315.18 (-2.76%)
AAPL   122.43 (-2.33%)
MSFT   230.42 (-1.76%)
FB   258.03 (-2.38%)
GOOGL   2,032.88 (-2.44%)
AMZN   3,097.80 (-1.95%)
TSLA   702.99 (-5.26%)
NVDA   538.10 (-7.22%)
BABA   242.77 (-3.02%)
CGC   34.01 (-4.47%)
GE   12.82 (-2.29%)
MU   89.75 (-2.99%)
NIO   48.35 (-6.77%)
AMD   82.97 (-4.57%)
T   28.73 (-2.21%)
F   11.89 (-3.10%)
ACB   11.15 (-4.21%)
DIS   192.91 (-2.33%)
BA   219.27 (-4.39%)
NFLX   542.55 (-1.96%)
BAC   36.09 (-0.80%)
S&P 500   3,847.31 (-1.99%)
DOW   31,510.54 (-1.41%)
QQQ   315.18 (-2.76%)
AAPL   122.43 (-2.33%)
MSFT   230.42 (-1.76%)
FB   258.03 (-2.38%)
GOOGL   2,032.88 (-2.44%)
AMZN   3,097.80 (-1.95%)
TSLA   702.99 (-5.26%)
NVDA   538.10 (-7.22%)
BABA   242.77 (-3.02%)
CGC   34.01 (-4.47%)
GE   12.82 (-2.29%)
MU   89.75 (-2.99%)
NIO   48.35 (-6.77%)
AMD   82.97 (-4.57%)
T   28.73 (-2.21%)
F   11.89 (-3.10%)
ACB   11.15 (-4.21%)
DIS   192.91 (-2.33%)
BA   219.27 (-4.39%)
NFLX   542.55 (-1.96%)
BAC   36.09 (-0.80%)
S&P 500   3,847.31 (-1.99%)
DOW   31,510.54 (-1.41%)
QQQ   315.18 (-2.76%)
AAPL   122.43 (-2.33%)
MSFT   230.42 (-1.76%)
FB   258.03 (-2.38%)
GOOGL   2,032.88 (-2.44%)
AMZN   3,097.80 (-1.95%)
TSLA   702.99 (-5.26%)
NVDA   538.10 (-7.22%)
BABA   242.77 (-3.02%)
CGC   34.01 (-4.47%)
GE   12.82 (-2.29%)
MU   89.75 (-2.99%)
NIO   48.35 (-6.77%)
AMD   82.97 (-4.57%)
T   28.73 (-2.21%)
F   11.89 (-3.10%)
ACB   11.15 (-4.21%)
DIS   192.91 (-2.33%)
BA   219.27 (-4.39%)
NFLX   542.55 (-1.96%)
BAC   36.09 (-0.80%)
S&P 500   3,847.31 (-1.99%)
DOW   31,510.54 (-1.41%)
QQQ   315.18 (-2.76%)
AAPL   122.43 (-2.33%)
MSFT   230.42 (-1.76%)
FB   258.03 (-2.38%)
GOOGL   2,032.88 (-2.44%)
AMZN   3,097.80 (-1.95%)
TSLA   702.99 (-5.26%)
NVDA   538.10 (-7.22%)
BABA   242.77 (-3.02%)
CGC   34.01 (-4.47%)
GE   12.82 (-2.29%)
MU   89.75 (-2.99%)
NIO   48.35 (-6.77%)
AMD   82.97 (-4.57%)
T   28.73 (-2.21%)
F   11.89 (-3.10%)
ACB   11.15 (-4.21%)
DIS   192.91 (-2.33%)
BA   219.27 (-4.39%)
NFLX   542.55 (-1.96%)
BAC   36.09 (-0.80%)
Log in
NASDAQ:GH

Guardant Health Stock Forecast, Price & News

$150.66
-11.58 (-7.14 %)
(As of 02/25/2021 01:22 PM ET)
Add
Compare
Today's Range
$146.00
Now: $150.66
$154.96
50-Day Range
$129.54
MA: $159.86
$179.10
52-Week Range
$55.90
Now: $150.66
$181.07
Volume60,450 shs
Average Volume1.06 million shs
Market Capitalization$15.06 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.57
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications. It also provides LUNAR-1 for minimal residual disease and recurrence detection in cancer survivors. In addition, the company is developing LUNAR-2 for early detection of cancer in higher risk individuals. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. The company has a collaboration agreement with Radius Health, Inc. to develop liquid biopsy companion diagnostic for elacestrant; and has partnership with Vall d'Hebron Institute of Oncology to establish first guardant-based liquid biopsy testing service in Europe. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone855-698-8887
Employees622
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$214.38 million
Book Value$8.50 per share

Profitability

Net Income$-75,650,000.00

Miscellaneous

Market Cap$15.06 billion
Next Earnings Date5/6/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.72 out of 5 stars

Medical Sector

437th out of 1,957 stocks

Medical Laboratories Industry

7th out of 39 stocks

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$150.66
-11.58 (-7.14 %)
(As of 02/25/2021 01:22 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GH News and Ratings via Email

Sign-up to receive the latest news and ratings for GH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Guardant Health (NASDAQ:GH) Frequently Asked Questions

Is Guardant Health a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Guardant Health stock.
View analyst ratings for Guardant Health
or view top-rated stocks.

What stocks does MarketBeat like better than Guardant Health?

Wall Street analysts have given Guardant Health a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Guardant Health wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Guardant Health's next earnings date?

Guardant Health is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Guardant Health
.

How were Guardant Health's earnings last quarter?

Guardant Health, Inc. (NASDAQ:GH) released its quarterly earnings results on Wednesday, February, 24th. The company reported ($0.94) earnings per share for the quarter, missing the consensus estimate of ($0.44) by $0.50. Guardant Health had a negative net margin of 67.14% and a negative trailing twelve-month return on equity of 19.22%.
View Guardant Health's earnings history
.

How has Guardant Health's stock been impacted by COVID-19?

Guardant Health's stock was trading at $62.95 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, GH shares have increased by 135.1% and is now trading at $148.00.
View which stocks have been most impacted by COVID-19
.

What guidance has Guardant Health issued on next quarter's earnings?

Guardant Health updated its FY 2021 After-Hours earnings guidance on Wednesday, February, 24th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $360-370 million, compared to the consensus revenue estimate of $377.07 million.

What price target have analysts set for GH?

9 brokers have issued 1-year target prices for Guardant Health's shares. Their forecasts range from $130.00 to $195.00. On average, they expect Guardant Health's share price to reach $166.00 in the next year. This suggests a possible upside of 12.2% from the stock's current price.
View analysts' price targets for Guardant Health
or view top-rated stocks among Wall Street analysts.

Who are Guardant Health's key executives?

Guardant Health's management team includes the following people:
  • Mr. AmirAli Talasaz, Pres, COO & Chairman (Age 41, Pay $914.91k)
  • Dr. Helmy Eltoukhy Ph.D., Co-Founder, CEO & Director (Age 42, Pay $914.91k)
  • Dr. Richard B. Lanman, Advisor (Age 66, Pay $540.15k)
  • Mr. Michael Bell, Chief Financial Officer (Age 52)
  • Mr. Kumud Kalia, Chief Information Officer
  • Mr. John G. Saia, Sr. VP, Gen. Counsel & Corp. Sec. (Age 48)
  • Ms. Amelia Merrill, VP of People
  • Mr. Mark Jacobstein, Chief User Engagement Officer
  • Mr. Andy Ament, Sr. VP of Operations
  • Mr. Daniel Simon, Sr. VP of Biopharma Bus. Devel.

What is Helmy Eltoukhy's approval rating as Guardant Health's CEO?

52 employees have rated Guardant Health CEO Helmy Eltoukhy on Glassdoor.com. Helmy Eltoukhy has an approval rating of 95% among Guardant Health's employees. This puts Helmy Eltoukhy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Guardant Health's key competitors?

What other stocks do shareholders of Guardant Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA), The Trade Desk (TTD), Square (SQ), Alibaba Group (BABA), PayPal (PYPL), Shopify (SHOP), Okta (OKTA), Alteryx (AYX), Roku (ROKU) and Twilio (TWLO).

When did Guardant Health IPO?

(GH) raised $200 million in an initial public offering on Thursday, October 4th 2018. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.

What is Guardant Health's stock symbol?

Guardant Health trades on the NASDAQ under the ticker symbol "GH."

Who are Guardant Health's major shareholders?

Guardant Health's stock is owned by a number of retail and institutional investors. Top institutional investors include SB Investment Advisers UK Ltd. (6.34%), BlackRock Inc. (5.33%), Morgan Stanley (4.94%), Viking Global Investors LP (3.54%), Clearbridge Investments LLC (3.18%) and Jennison Associates LLC (3.01%). Company insiders that own Guardant Health stock include Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Michael J Wiley, Richard B Lanman, Samir Kaul, Stanley J Meresman, Timothy P Eckersley and Vision Fund (Aiv M1) Softbank.
View institutional ownership trends for Guardant Health
.

Which major investors are selling Guardant Health stock?

GH stock was sold by a variety of institutional investors in the last quarter, including SB Investment Advisers UK Ltd., Morgan Stanley, Nuveen Asset Management LLC, Viking Global Investors LP, Jennison Associates LLC, Clearbridge Investments LLC, Frontier Capital Management Co. LLC, and Rhenman & Partners Asset Management AB. Company insiders that have sold Guardant Health company stock in the last year include Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Michael J Wiley, Samir Kaul, and Stanley J Meresman.
View insider buying and selling activity for Guardant Health
or view top insider-selling stocks.

Which major investors are buying Guardant Health stock?

GH stock was acquired by a variety of institutional investors in the last quarter, including Ardevora Asset Management LLP, Orbimed Advisors LLC, JPMorgan Chase & Co., BlackRock Inc., First Trust Advisors LP, FIL Ltd, PFM Health Sciences LP, and Barclays PLC.
View insider buying and selling activity for Guardant Health
or or view top insider-buying stocks.

How do I buy shares of Guardant Health?

Shares of GH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Guardant Health's stock price today?

One share of GH stock can currently be purchased for approximately $148.00.

How much money does Guardant Health make?

Guardant Health has a market capitalization of $14.80 billion and generates $214.38 million in revenue each year. The company earns $-75,650,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis.

How many employees does Guardant Health have?

Guardant Health employs 622 workers across the globe.

What is Guardant Health's official website?

The official website for Guardant Health is www.guardanthealth.com.

Where are Guardant Health's headquarters?

Guardant Health is headquartered at 505 PENOBSCOT DR., REDWOOD CITY CA, 94063.

How can I contact Guardant Health?

Guardant Health's mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The company can be reached via phone at 855-698-8887.


This page was last updated on 2/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.